Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies

Launched by NATIONAL CANCER INSTITUTE (NCI) · Apr 22, 2010

Keywords

ClinConnect Summary

This clinical trial is focused on collecting and storing samples from individuals diagnosed with common childhood cancers, such as leukemia, sarcoma, neuroblastoma, retinoblastoma, and renal cancer. The goal is to create a tissue repository that will help researchers study these cancers more effectively. By gathering blood, tissue, urine, and tumor samples from both children and adults, scientists hope to better understand these diseases and potentially improve treatment options in the future.

To participate in the trial, individuals must have been diagnosed with a type of childhood cancer or be a biological relative of someone affected by such cancers. Healthy volunteers who don’t have a history of cancer but are undergoing surgery or treatment may also be eligible. Participants can expect that samples will be collected during routine medical care, so no extra procedures will be required solely for this study. It's important for participants or their guardians to understand and agree to the study's terms by signing an informed consent document. Overall, this trial aims to enhance knowledge and research related to childhood cancers, which could lead to better outcomes for patients.

Gender

ALL

Eligibility criteria

• * SUBJECT INCLUSION CRITERIA:
• Pediatric or adult subjects with one of the following:
• • Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;
• • Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;
• • Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;
• • Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
• • Human samples, specimens and data collected on IRB approved protocols that are now closed
• • Ability of subject, Legally Authorized Representative (LAR), or parent/legal guardian of children less than or equal to 18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.
• Inclusion Criteria for Social and Behavioral Outcome Interviews:
• • Parent/caregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.
• • Must be able to give consent and sign the informed consent document.
• • Able to understand the English language.
• EXCLUSION CRITERIA:
• • None